Literature DB >> 17699259

Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation.

Masako Ueda1, Kevin O'Brien, Douglas R Rosing, Alexander Ling, Robert Kleta, Dorothea McAreavey, Isa Bernardini, William A Gahl.   

Abstract

Cystinosis, an autosomal recessive disorder of lysosomal cystine accumulation, results from mutations in the CTNS gene that encodes the lysosomal cystine transporter, cystinosin. Renal tubular Fanconi syndrome occurs in infancy, followed by rickets, growth retardation, photophobia, and renal failure, which requires renal transplantation at approximately 10 yr of age. Treatment with cysteamine decreases cellular cystine levels, retards renal deterioration, and allows for normal growth. Patients with a history of inadequate cystine depletion therapy may survive, after renal transplantation, into the third to fifth decades but will experience other, extrarenal complications of the disease. Routine chest and head computed tomography scans of 41 posttransplantation patients with cystinosis were reviewed for vascular calcification. The radiologic procedures had been performed to examine lung and brain parenchyma, so there was little ascertainment bias. Thirteen of the 41 patients had vascular calcification, including 11 with coronary artery calcification. One 25-yr-old man required three-vessel coronary artery bypass graft surgery. There were no significant differences between the 13 patients with calcification and the 28 without calcification in the following parameters: Time on dialysis, frequency of transplantation, hypertension, hypercholesterolemia, homozygosity for the 57-kb deletion in CTNS, serum creatinine, and calcium-phosphate product. However, the finding of vascular calcification correlated directly with duration of life without cysteamine therapy and inversely with duration of life under good cystine-depleting therapy. The accumulation of intracellular cystine itself maybe a risk factor for vascular calcifications, and older patients with cystinosis should be screened for this complication.

Entities:  

Mesh:

Year:  2006        PMID: 17699259     DOI: 10.2215/CJN.01431005

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  13 in total

1.  Progressive destructive bone changes in patients with cystinosis.

Authors:  Maria Klusmann; William Van't Hoff; Fergal Monsell; Amaka C Offiah
Journal:  Skeletal Radiol       Date:  2013-09-28       Impact factor: 2.199

2.  A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety.

Authors:  Craig B Langman; Larry A Greenbaum; Minnie Sarwal; Paul Grimm; Patrick Niaudet; Georges Deschênes; Elisabeth Cornelissen; Denis Morin; Pierre Cochat; Debora Matossian; Segolene Gaillard; Mary Jo Bagger; Patrice Rioux
Journal:  Clin J Am Soc Nephrol       Date:  2012-05-03       Impact factor: 8.237

Review 3.  The renal Fanconi syndrome in cystinosis: pathogenic insights and therapeutic perspectives.

Authors:  Stephanie Cherqui; Pierre J Courtoy
Journal:  Nat Rev Nephrol       Date:  2016-12-19       Impact factor: 28.314

Review 4.  Nephropathic cystinosis: late complications of a multisystemic disease.

Authors:  Galina Nesterova; William Gahl
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

5.  Chiari I Malformation in Nephropathic Cystinosis.

Authors:  Kavya I Rao; John Hesselink; Doris A Trauner
Journal:  J Pediatr       Date:  2015-08-08       Impact factor: 4.406

Review 6.  Adult complications of nephropathic cystinosis: a systematic review.

Authors:  Rachel Nora Kasimer; Craig B Langman
Journal:  Pediatr Nephrol       Date:  2020-02-03       Impact factor: 3.714

7.  Non-invasive measurements of atherosclerosis in adult cystinosis patients.

Authors:  Martine T P Besouw; Suzanne Holewijn; Elena N Levtchenko; Mirian C H Janssen
Journal:  J Inherit Metab Dis       Date:  2011-02-09       Impact factor: 4.982

Review 8.  Lysosome (Dys)function in Atherosclerosis-A Big Weight on the Shoulders of a Small Organelle.

Authors:  André R A Marques; Cristiano Ramos; Gisela Machado-Oliveira; Otília V Vieira
Journal:  Front Cell Dev Biol       Date:  2021-03-29

Review 9.  Cystinosis: the evolution of a treatable disease.

Authors:  Galina Nesterova; William A Gahl
Journal:  Pediatr Nephrol       Date:  2012-08-18       Impact factor: 3.714

10.  Cysteamine inhibits lysosomal oxidation of low density lipoprotein in human macrophages and reduces atherosclerosis in mice.

Authors:  Yichuan Wen; Feroz Ahmad; Zahra Mohri; Peter D Weinberg; David S Leake
Journal:  Atherosclerosis       Date:  2019-09-26       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.